Teijin Pharma Limited will launch Feburic (febuxostat, TMX-67), for treating hyperuricemia in Japan on May 17.
It effectively lowers the level of uric acid in the blood of hyperuricemic patients to the recommended level of less than 6.0mg/dL, and is well tolerated by patients suffering from mild to moderate renal impairment without any dose adjustment. The number of patients in Japan with hyperuricemia is estimated to be around 16 million.
Discovered in by Teijin Pharma in 1991, febuxostat is the first non-purine selective inhibitor of xanthine oxidase. Its chemical structure is different from that of allopurinol, which has been used for over 40 years as the standard treatment for hyperuricemia.
Febuxostat is marketed by licensees under the brand name Uloric in the United States and Canada, and under the brand name Adenuric in Europe.
Release Date: May 13, 2011
Source: Teijin Pharma
Filed Under: Drug Discovery